{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:25:37Z","timestamp":1793319937115,"version":"4.5.0"},"reference-count":59,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:p>The re-emergence of serotonergic psychedelics has introduced rapid-acting antidepressant effects and has been widely described as a paradigmatic shift in depression treatment. Recently, there has been intense debate about whether the acute subjective effects of psychedelics are necessary for their therapeutic efficacy or merely byproducts of underlying neuroplastic processes. Recent conceptualizations of \u201cpsychoplastogens\u201d emphasize rapid induction of neuroplasticity as a potential common pathway across mechanistically diverse rapid-acting antidepressants. Here, some argue that the psychedelic experience itself may not be required for enduring therapeutic change while others highlight the clinical and existential significance of the subjective experience and its integration within structured psychotherapeutic settings. This Perspective argues that the debate is often framed too narrowly as a binary opposition between experience and mechanism and opts for a complementary model in which receptor-level signalling, network reorganization, subjective experience, and psychotherapeutic context represent interacting dimensions of a single intervention architecture. Within this framework, subjective experience may be clinically meaningful without being biologically indispensable, while neuroplasticity may constitute an enabling condition without being sufficient in isolation. Rather than asking whether experience or mechanism is primary, the clinically relevant question becomes under which conditions, for which patients, and within which care structures different plasticity-inducing interventions, hallucinogenic or non-hallucinogenic, are most appropriate. This question is further complicated by methodological challenges in isolating those contributions empirically. Psychedelic research thus challenges not only neurobiological models of depression but also existing assumptions about how pharmacological and psychotherapeutic processes converge in antidepressant treatment.<\/jats:p>","DOI":"10.1177\/02698811261473402","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:26:08Z","timestamp":1786955168000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Experience, plasticity, and context: Beyond single-level models of antidepressant action"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1417-6929","authenticated-orcid":false,"given":"David","family":"Eckert","sequence":"first","affiliation":[{"name":"Psychiatric Services Thurgau, M\u00fcnsterlingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Aarrestad IK Cameron LP Fenton EM et al. (2025) The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation. Nature Neuroscience 28: 1919\u20131931. https:\/\/doi.org\/10.1038\/s41593-025-02021-1","DOI":"10.1038\/s41593-025-02021-1"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Aday JS Heifets BD Pratscher SD et al. (2022) Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology 239: 1989\u20132010. https:\/\/doi.org\/10.1007\/s00213-022-06123-7","DOI":"10.1007\/s00213-022-06123-7"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Aleksandrova LR Phillips AG Wang YT (2017) Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. Journal of Psychiatry and Neuroscience 42: 222\u2013229. https:\/\/doi.org\/10.1503\/jpn.160175","DOI":"10.1503\/jpn.160175"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Boku S Nakagawa S Toda H et al. (2018) Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry and Clinical Neurosciences 72: 3\u201312. https:\/\/doi.org\/10.1111\/pcn.12604","DOI":"10.1111\/pcn.12604"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Butler M Jelen L Rucker J (2022) Expectancy in placebo-controlled trials of psychedelics: If so so what? Psychopharmacology 239: 3047\u20133055. https:\/\/doi.org\/10.1007\/s00213-022-06221-6","DOI":"10.1007\/s00213-022-06221-6"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Carhart-Harris R Giribaldi B Watts R et al. (2021) Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384:1402\u20131411. https:\/\/doi.org\/10.1056\/NEJMoa2032994","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Cooper T Seigler MD Stahl S (2023) Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions. Journal of Psychopharmacology 37: 242\u2013247. https:\/\/doi.org\/10.1177\/02698811231158891","DOI":"10.1177\/02698811231158891"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Davis AK Barrett FS May DG et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78: 481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Drewko AJ Habets RLP Brunt TM (2025) Above the threshold beyond the trip: The role of the 5-HT2A receptor in psychedelic-induced neuroplasticity and antidepressant effects. Molecular Psychiatry 30: 5926\u20135937. https:\/\/doi.org\/10.1038\/s41380-025-03169-9","DOI":"10.1038\/s41380-025-03169-9"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Duan W Cao D Wang S et al. (2024) Serotonin 2A receptor (5-HT2AR) agonists: Psychedelics and non-hallucinogenic analogues as emerging antidepressants. Chemical Reviews 124: 124\u2013163. https:\/\/doi.org\/10.1021\/acs.chemrev.3c00375","DOI":"10.1021\/acs.chemrev.3c00375"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Estric C Duron T Kabani S et al. (2025) Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review. Journal of Psychopharmacology 39: 910\u2013929. https:\/\/doi.org\/10.1177\/02698811251338214","DOI":"10.1177\/02698811251338214"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Goodwin GM Aaronson ST Alvarez O et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 387: 1637\u20131648. https:\/\/doi.org\/10.1056\/NEJMoa2206443","DOI":"10.1056\/NEJMoa2206443"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Goodwin GM Aaronson ST Alvarez O et al. (2025) The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression. Journal of Affective Disorders 372: 523\u2013532. https:\/\/doi.org\/10.1016\/j.jad.2024.12.061","DOI":"10.1016\/j.jad.2024.12.061"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Goodwin GM Malievskaia E Fonzo GA et al. (2024) Psychological support for psilocybin treatment: Reply to letters on our commentary. American Journal of Psychiatry 181: 79\u201381. https:\/\/doi.org\/10.1176\/appi.ajp.20230905","DOI":"10.1176\/appi.ajp.20230905"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Grossman DH Madden KM Mehtani NJ et al. (2025) A systematic review of income and education reporting in psychedelic clinical trials. Nature Mental Health 3: 567\u2013574. https:\/\/doi.org\/10.1038\/s44220-025-00417-3","DOI":"10.1038\/s44220-025-00417-3"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Hayes SC (2016) Acceptance and commitment therapy relational frame theory and the third wave of behavioral and cognitive therapies\u2013republished article. Behavior Therapy 47: 869\u2013885. https:\/\/doi.org\/10.1016\/j.beth.2016.11.006","DOI":"10.1016\/j.beth.2016.11.006"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1037\/10628-000"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Hughes ME Garcia-Romeu A (2024) Ethnoracial inclusion in clinical trials of psychedelics: A systematic review. EClinicalMedicine 74: 102711. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102711","DOI":"10.1016\/j.eclinm.2024.102711"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Husain MI Ledwos N Fellows E et al. (2022) Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action? Frontiers in Psychiatry 13: 1076459. https:\/\/doi.org\/10.3389\/fpsyt.2022.1076459.","DOI":"10.3389\/fpsyt.2022.1076459"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Ippolito A Vasudevan S Hurley S et al. (2025) Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs. British Journal of Pharmacology 183: 4058\u20134071. https:\/\/doi.org\/10.1111\/bph.70109","DOI":"10.1111\/bph.70109"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Kishon R Cycowicz YM (2025) Psychedelic therapy: Bridging neuroplasticity phenomenology and clinical outcomes. Frontiers in Psychiatry 16: 1637162. https:\/\/doi.org\/10.3389\/fpsyt.2025.1637162","DOI":"10.3389\/fpsyt.2025.1637162"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Kittur ME Burgos MLA Jones BDM et al. (2025) Mapping psilocybin therapy: A systematic review of therapeutic frameworks adaptations and standardization across contemporary clinical trials. Journal of Affective Disorders 391: 119952. https:\/\/doi.org\/10.1016\/j.jad.2025.119952","DOI":"10.1016\/j.jad.2025.119952"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Ko K Knight G Rucker JJ et al. (2022) Psychedelics mystical experience and therapeutic efficacy: A systematic review. Frontiers in Psychiatry 13: 917199. https:\/\/doi.org\/10.3389\/fpsyt.2022.917199","DOI":"10.3389\/fpsyt.2022.917199"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Kwan AC Olson DE Preller KH et al. (2022) The neural basis of psychedelic action. Nature Neuroscience 25:1407\u20131419. https:\/\/doi.org\/10.1038\/s41593-022-01177-4","DOI":"10.1038\/s41593-022-01177-4"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Lii TR Smith AE Flohr JR et al. (2023) Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nature Mental Health 1: 876\u2013886. https:\/\/doi.org\/10.1038\/s44220-023-00140-x","DOI":"10.1038\/s44220-023-00140-x"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Ling S Ceban F Lui LMW et al. (2022) Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs 36: 17\u201330. https:\/\/doi.org\/10.1007\/s40263-021-00877-y","DOI":"10.1007\/s40263-021-00877-y"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Liu B Liu J Wang M et al. (2017) From serotonin to neuroplasticity: Evolvement of theories for major depressive disorder. Frontiers in Cellular Neuroscience 11: 305. https:\/\/doi.org\/10.3389\/fncel.2017.00305","DOI":"10.3389\/fncel.2017.00305"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Lu J Tjia M Mullen B et al. (2021) An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Molecular Psychiatry 26: 6237\u20136252. https:\/\/doi.org\/10.1038\/s41380-021-01159-1","DOI":"10.1038\/s41380-021-01159-1"},{"key":"e_1_3_3_30_1","doi-asserted-by":"crossref","unstructured":"Lv S Yao K Zhang Y et al. (2023) NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research. Neuropharmacology 225: 109378. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109378","DOI":"10.1016\/j.neuropharm.2022.109378"},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"McClure-Begley TD Roth BL (2022) The promises and perils of psychedelic pharmacology for psychiatry. Nature Reviews Drug Discovery 21: 463\u2013473. https:\/\/doi.org\/10.1038\/s41573-022-00421-7","DOI":"10.1038\/s41573-022-00421-7"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"McIntyre RS (2023) Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual discovery development and implementation implications for psilocybin and related agents. Expert Opinion on Drug Safety 22: 885\u2013889. https:\/\/doi.org\/10.1080\/14740338.2023.2253144","DOI":"10.1080\/14740338.2023.2253144"},{"key":"e_1_3_3_33_1","doi-asserted-by":"crossref","unstructured":"Moliner R Girych M Brunello CA et al. (2023) Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience 26: 1032\u20131041. https:\/\/doi.org\/10.1038\/s41593-023-01316-5","DOI":"10.1038\/s41593-023-01316-5"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Muthukumaraswamy SD Forsyth A Lumley T (2021) Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology 14: 1133\u20131152. https:\/\/doi.org\/10.1080\/17512433.2021.1933434","DOI":"10.1080\/17512433.2021.1933434"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Nicholas CR Banks MI Lennertz RC et al. 2024. Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience. Translational Psychiatry 14: 372. https:\/\/doi.org\/10.1038\/s41398-024-03059-8","DOI":"10.1038\/s41398-024-03059-8"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Nikolaidis A Lancelotta R Gukasyan N et al. (2023) Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders 324: 239\u2013249. https:\/\/doi.org\/10.1016\/j.jad.2022.12.042","DOI":"10.1016\/j.jad.2022.12.042"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Nutt DJ Peill JM Weiss B et al. (2024) Psilocybin and other classic psychedelics in depression. Current Topics in Behavioral Neurosciences 66: 149\u2013174. https:\/\/doi.org\/10.1007\/7854_2023_451","DOI":"10.1007\/7854_2023_451"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell KC Anderson BT Barrett FS et al. (2024) Misinterpretations and omissions: A critical response to Goodwin and colleagues\u2019 commentary on psilocybin-assisted therapy. American Journal of Psychiatry 181: 74\u201375. https:\/\/doi.org\/10.1176\/appi.ajp.20230661","DOI":"10.1176\/appi.ajp.20230661"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell P Etkin A Manji H (2026) Brain neuroplasticity mechanisms in psychiatric illnesses and in the development of novel treatments. American Journal of Psychiatry 183: 98\u2013107. https:\/\/doi.org\/10.1176\/appi.ajp.20251212","DOI":"10.1176\/appi.ajp.20251212"},{"key":"e_1_3_3_40_1","doi-asserted-by":"crossref","unstructured":"Olson DE (2021) The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science 4: 563\u2013567. https:\/\/doi.org\/10.1021\/acsptsci.0c00192","DOI":"10.1021\/acsptsci.0c00192"},{"key":"e_1_3_3_41_1","doi-asserted-by":"crossref","unstructured":"Olson DE (2022) Biochemical mechanisms underlying psychedelic-induced neuroplasticity. Biochemistry 61: 127\u2013136. https:\/\/doi.org\/10.1021\/acs.biochem.1c00812","DOI":"10.1021\/acs.biochem.1c00812"},{"key":"e_1_3_3_42_1","doi-asserted-by":"crossref","unstructured":"Page CE Epperson CN Novick AM et al. (2024) Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder. Molecular Psychiatry 29: 3802\u20133813. https:\/\/doi.org\/10.1038\/s41380-024-02625-2","DOI":"10.1038\/s41380-024-02625-2"},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","unstructured":"Palitsky R Kaplan DM Peacock C et al. (2023) Importance of integrating spiritual existential religious and theological components in psychedelic-assisted therapies. JAMA Psychiatry 80: 743\u2013749. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.1554.","DOI":"10.1001\/jamapsychiatry.2023.1554"},{"key":"e_1_3_3_44_1","doi-asserted-by":"crossref","unstructured":"Payne BK Hall DL Cameron CD et al. (2010) A process model of affect misattribution. Personality and Social Psychology Bulletin 36: 1397\u20131408. https:\/\/doi.org\/10.1177\/0146167210383440","DOI":"10.1177\/0146167210383440"},{"key":"e_1_3_3_45_1","doi-asserted-by":"crossref","unstructured":"Pittenger C Duman RS (2008) Stress depression and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacol 33:88\u2013109. https:\/\/doi.org\/10.1038\/sj.npp.1301574","DOI":"10.1038\/sj.npp.1301574"},{"key":"e_1_3_3_46_1","doi-asserted-by":"crossref","unstructured":"Puigseslloses P Nadal-Gratac\u00f3s N Fum\u00e0s B et al. (2025) Neuropharmacology of halogenated DMT analogs: Psychoplastogenic and antidepressant properties of 5-Br-DMT a psychedelic derivative with low hallucinogenic potential. Molecular Psychiatry 31: 1733\u20131745. https:\/\/doi.org\/10.1038\/s41380-025-03308-2","DOI":"10.1038\/s41380-025-03308-2"},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","unstructured":"Raison CL Sanacora G Woolley J et al. (2023) Single-dose psilocybin treatment for major depressive disorder: A randomized clinical trial. JAMA 330: 843\u2013853. https:\/\/doi.org\/10.1001\/jama.2023.14530","DOI":"10.1001\/jama.2023.14530"},{"key":"e_1_3_3_48_1","doi-asserted-by":"crossref","unstructured":"Reiff CM Richman EE Nemeroff CB et al. (2020) Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry 177: 391\u2013410. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010035","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"e_1_3_3_49_1","doi-asserted-by":"crossref","unstructured":"Roseman L Nutt DJ Carhart-Harris RL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology 8: 974. https:\/\/doi.org\/10.3389\/fphar.2017.00974","DOI":"10.3389\/fphar.2017.00974"},{"key":"e_1_3_3_50_1","doi-asserted-by":"crossref","unstructured":"Siegel JS Liston C Nicol GE et al. (2026) The science of psychedelic medicine. Nature Medicine 32: 449\u2013462. https:\/\/doi.org\/10.1038\/s41591-025-04194-5","DOI":"10.1038\/s41591-025-04194-5"},{"key":"e_1_3_3_51_1","doi-asserted-by":"crossref","unstructured":"Sloshower J Skosnik PD Safi-Aghdam H et al. (2023) Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled fixed-order trial. Journal of Psychopharmacology 37: 698\u2013706. https:\/\/doi.org\/10.1177\/02698811231154852","DOI":"10.1177\/02698811231154852"},{"key":"e_1_3_3_52_1","doi-asserted-by":"crossref","unstructured":"Sloshower J Zeifman RJ Guss J et al. (2024) Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: Results from an exploratory placebo-controlled trial. Scientific Reports 14: 8833. https:\/\/doi.org\/10.1038\/s41598-024-58318-x","DOI":"10.1038\/s41598-024-58318-x"},{"key":"e_1_3_3_53_1","doi-asserted-by":"crossref","unstructured":"Stoliker D Novelli L Vollenweider FX et al. (2024) Neural mechanisms of resting-state networks and the amygdala underlying the cognitive and emotional effects of psilocybin. Biological Psychiatry 96: 57\u201366. https:\/\/doi.org\/10.1016\/j.biopsych.2024.01.002","DOI":"10.1016\/j.biopsych.2024.01.002"},{"key":"e_1_3_3_54_1","doi-asserted-by":"crossref","unstructured":"van Elk M Yaden DB (2022) Pharmacological neural and psychological mechanisms underlying psychedelics: A critical review. Neuroscience & Biobehavioral Reviews 140: 104793. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104793","DOI":"10.1016\/j.neubiorev.2022.104793"},{"key":"e_1_3_3_55_1","doi-asserted-by":"crossref","unstructured":"Vargas MV Meyer R Avanes AA et al. (2021) Psychedelics and Other Psychoplastogens for Treating Mental Illness. Frontiers in Psychiatry 12: 727117. https:\/\/doi.org\/10.3389\/fpsyt.2021.727117","DOI":"10.3389\/fpsyt.2021.727117"},{"key":"e_1_3_3_56_1","doi-asserted-by":"crossref","unstructured":"von Rotz R Schindowski EM Jungwirth J et al. (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled double-blind randomised clinical trial. EClinicalMedicine 56: 101809. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101809","DOI":"10.1016\/j.eclinm.2022.101809"},{"key":"e_1_3_3_57_1","doi-asserted-by":"crossref","unstructured":"Wallach J Cao AB Calkins MM et al. (2023) Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nature Communications 14: 8221. https:\/\/doi.org\/10.1038\/s41467-023-44016-1","DOI":"10.1038\/s41467-023-44016-1"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1037\/0033-295X.92.4.548"},{"key":"e_1_3_3_59_1","doi-asserted-by":"crossref","unstructured":"Wolff M Evens R Mertens LJ et al. (2024) Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ). Journal of Psychopharmacology 38: 432\u2013457. https:\/\/doi.org\/10.1177\/02698811241249698","DOI":"10.1177\/02698811241249698"},{"key":"e_1_3_3_60_1","doi-asserted-by":"crossref","unstructured":"Xu Z Wang H Yu J et al. (2026) Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling. Nature 651: 829\u2013837. https:\/\/doi.org\/10.1038\/s41586-026-10249-5","DOI":"10.1038\/s41586-025-10061-7"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261473402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:49:47Z","timestamp":1787298587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261473402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":59,"alternative-id":["10.1177\/02698811261473402"],"URL":"https:\/\/doi.org\/10.1177\/02698811261473402","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"02698811261473402"}}